D.C. Week: CBO Still Sees Surge in Uninsured with AHCA
(MedPage Today) -- Also: FDA panel backs new breast cancer drug, Epogen biosimilar (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 27, 2017 Category: Dermatology Source Type: news
Epoetin Alfa Biosimilar Clears FDA Hurdle
(MedPage Today) -- Near-unanimous support from advisory committee (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 25, 2017 Category: American Health Source Type: news
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen ® / Procrit® across all indications
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee. (Source: World Pharma News)
Source: World Pharma News - May 25, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Epogen (Epoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 27, 2017 Category: Drugs & Pharmacology Source Type: news
EPREX ® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 24, 2017 Category: Pharmaceuticals Source Type: news
Amgen And DaVita Enter Into New Sourcing And Supply Agreement
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc. This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients.
Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico. The...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Procrit (Epoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 13, 2016 Category: Drugs & Pharmacology Source Type: news
Hospira Submits Biologics License Application to FDA
The application was for a proposed epoetin alfa biosimilar (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 12, 2015 Category: Pharmaceuticals Source Type: news
FDA Approves ‘ Biosimilar ’ Drug to Treat Certain Types of Anemia
Retacrit is biosimilar to the drugs Epogen and Procrit (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, AIDS, Institutional, Source Type: news
Roxadustat Noninferior to Epoetin Alfa in Dialysis Patients
And for anemia in patients with kidney disease not undergoing dialysis, roxadustat is superior to placebo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news
Express Scripts Drops Amgen Anemia Drugs From FormularyExpress Scripts Drops Amgen Anemia Drugs From Formulary
Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Internal Medicine News Source Type: news
Express Scripts drops Amgen anemia drugs from formulary
(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 29, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Epoetin Alfa Market & Erythropoietin Industry in China 2018...
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store.(PRWeb March 11, 2014)Read the full story at http://www.prweb.com/releases/2018-china-epoetin-alfa/epo-industry-report/prweb11658217.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2014 Category: Pharmaceuticals Source Type: news
Anemia in breast cancer patients reduced by epoetin alfa with no negative impact on survival
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published in the Journal of the National Cancer Institute. To investigate the safety and efficacy of epoetin alfa, Volker Moebus, M.D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
